Milestone Therapy Revenue and Competitors
Estimated Revenue & Valuation
- Milestone Therapy's estimated annual revenue is currently $15.8M per year.
- Milestone Therapy's estimated revenue per employee is $243,000
Employee Data
- Milestone Therapy has 65 Employees.
- Milestone Therapy grew their employee count by 67% last year.
Milestone Therapy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 17 | -47% | N/A | N/A |
#2 | $12.6M | 52 | 6% | N/A | N/A |
#3 | $5.3M | 28 | -3% | N/A | N/A |
#4 | $7.8M | 36 | 38% | N/A | N/A |
#5 | $5.1M | 27 | -7% | N/A | N/A |
#6 | $22.1M | 82 | 1% | N/A | N/A |
#7 | $101.6M | 301 | 4% | N/A | N/A |
#8 | $4.7M | 25 | -24% | N/A | N/A |
#9 | $0.3M | 2 | -33% | N/A | N/A |
#10 | $0.8M | 6 | -76% | N/A | N/A |
What Is Milestone Therapy?
Milestone Therapy specializes in home-based pediatric Occupational Therapy, Physical Therapy and Speech Therapy. Our staff is comprised of highly trained therapists that not only understand the unique needs of children, but are truly passionate about improving the lives of children. We strive to help all our clients reach their goals and graduate from therapy both physically and mentally stronger.
keywords:N/AN/A
Total Funding
65
Number of Employees
$15.8M
Revenue (est)
67%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Milestone Therapy News
... $50M milestone under J&J collaboration deal for cancer therapy ... Johnson's (NYSE:JNJ) Janssen Biotech for CAR-T therapy cilta-cel,...
Changes to the federal government's developmental milestone ... of Pediatrics met with the American Physical Therapy Association in March...
The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.2M | 65 | 55% | $8.9M |
#2 | $12.3M | 65 | 7% | N/A |
#3 | $14.6M | 65 | 0% | N/A |
#4 | $15.8M | 65 | 67% | N/A |
#5 | $7.5M | 65 | 2% | N/A |